137 results
Page 2 of 7
6-K
EX-99
20eltkgubs
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
01tugm wnxm
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
4z658mu
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-99
z9b7 a0njt
30 Aug 23
Current report (foreign)
6:45am
6-K
EX-1
w3dm9j 021zfc
17 Jul 23
BioLineRx Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic
7:10am
6-K
EX-99
td6ay61u
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
y3z e60iwi5zzs
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
4oabhto owvuvq
25 Apr 23
Current report (foreign)
7:07am
6-K
EX-99
7cymrqdrq5vh ooo
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
EX-10.1
fv8gb9sft0
21 Sep 22
Current report (foreign)
8:00am
6-K
EX-99
ocnfav
27 May 22
2022 Annual General Meeting of Shareholders
4:30pm
6-K
EX-10.1
0wb4p5 al1
3 Sep 21
Current report (foreign)
4:30pm
424B5
bg51ym0b
3 Sep 21
Prospectus supplement for primary offering
4:29pm
POS AM
i3e idlnks
23 Feb 21
Prospectus update (post-effective amendment)
9:12am
6-K
EX-99
olotyufkw2ewypuw
21 Jan 21
Amended and Restated Underwriting Agreement
4:32pm
424B5
ubd8pkt3zm rdweggg9e
21 Jan 21
Prospectus supplement for primary offering
4:31pm